Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma | MicrobiomeTrials← Back to trialsNCT06830031
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-03-25Est. Completion: 2029-04-28
Enrollment target: 18 participants Locations- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
Other microbiome trials you might be interested in
Non-hodgkin Lymphoma
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell l…
Palo Alto, United StatesEst. completion Nov 2028
B-cell MalignancyMarginal Zone LymphomaFollicular LymphomaNon-Hodgkin LymphomaWaldenström MacroglobulinemiaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Mantle Cell Lymphoma
Diffuse Large B Cell Lymphoma
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprise…
Birmingham, United StatesEst. completion Nov 2026
Diffuse Large B-Cell Lymphoma UnclassifiableRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as init…
Duarte, United StatesEst. completion Jul 26, 2022